Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.
Helse i Hardanger, Øystese, Norway.
BMC Psychiatry. 2024 May 14;24(1):361. doi: 10.1186/s12888-024-05786-0.
A concentrated transdiagnostic and micro choice-based group treatment for patients with depression and anxiety has previously shown to yield significant reduction in symptoms and increased level of functioning from pre to 3-month follow-up. In the present study, we report the results after 12 months follow-up.
This was a non-randomized clinical intervention pilot study, conducted in line with a published protocol. Sixty-seven consecutively referred patients, aged 19-47 (mean age 32.5, SD = 8.0) were included and completed treatment. All had a severity of their problems that entitled them to care in the specialist public mental health care. Self-reported age at onset of symptoms was 17.6 (SD = 7.9) years. Mean number of prior treatment courses was 3.5 (SD = 3.3; range 0-20). The main objective was to assess the treatment effectiveness by questionnaires measuring relevant symptoms at pre-treatment, 7 days-, 3 months-, 6 months- and at 12-months follow-up.
Validated measures of functional impairment (WSAS), depression (PHQ9), anxiety (GAD7), worry (PSWQ), fatigue (CFQ), insomnia (BIS) and illness perception (BIPQ) improved significantly (p < .0005) from before treatment to 12 months follow-up, yielding mostly large to extremely large effect sizes (0.89-3.68), whereas some moderate (0.60-0.76). After 12 months, 74% report an overall improvement in problems related to anxiety and depression. Utilization of specialist, public and private mental health care was reported as nonexistent or had decreased for 70% of the patients at 12-month follow up.
The concentrated, micro-choice based group treatment approach yielded a highly clinically significant reduction in a wide range of symptoms already one week after treatment, and the positive results persisted at 12-month follow-up.
ClinicalTrials.gov Identifier: NCT05234281, first posted date 10/02/2022.
先前的研究表明，针对抑郁和焦虑患者的集中式跨诊断和微选择的小组治疗可显著减轻症状，并提高从治疗前到 3 个月随访期间的功能水平。在本研究中，我们报告了 12 个月随访后的结果。
这是一项非随机临床干预性试点研究，按照已发表的方案进行。共纳入 67 名连续转诊的患者，年龄 19-47 岁（平均年龄 32.5，标准差=8.0），并完成了治疗。所有患者的问题严重程度都符合在专科公共精神卫生保健机构接受治疗的标准。自我报告的症状出现年龄为 17.6（标准差=7.9）岁。平均治疗疗程数为 3.5（标准差=3.3；范围 0-20）。主要目标是通过在治疗前、治疗后 7 天、3 个月、6 个月和 12 个月随访时评估问卷来评估治疗效果，评估相关症状。
有效的功能障碍（WSAS）、抑郁（PHQ9）、焦虑（GAD7）、担忧（PSWQ）、疲劳（CFQ）、失眠（BIS）和疾病认知（BIPQ）测量指标在治疗前至 12 个月随访期间显著改善（p<.0005），产生的效应量大多为大到极大（0.89-3.68），而有些为中（0.60-0.76）。12 个月后，74%的患者报告焦虑和抑郁相关问题总体改善。70%的患者在 12 个月随访时报告称，专科、公共和私人精神卫生保健的使用情况为不存在或减少。
集中式、基于微选择的小组治疗方法在治疗后一周内即可显著减轻广泛的症状，且积极的结果在 12 个月随访时仍然存在。
ClinicalTrials.gov 标识符：NCT05234281，首次注册日期 2022 年 10 月 2 日。
